Recurrence of cholestatic liver disease after living donor liver transplantation.
End-stage liver disease, due to cholestatic liver diseases with an autoimmune background such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), is considered a good indication for liver transplantation. Excellent overall patient and graft outcomes, based mostly on the experience from deceased donor liver transplantation (DDLT), have been reported. Due to the limited number of organ donations from deceased donors in most Asian countries, living donor liver transplantation (LDLT) is the mainstream treatment for end-stage liver disease, including that resulting from PBC and PSC. Although the initial experiences with LDLT for PBC and PSC seem satisfactory or comparable to that with DDLT, some aspects, including the timing of transplantation, the risk of recurrent disease, and its long-term clinical implications, require further evaluation. Whether or not the long-term outcomes of LDLT from a biologically related donor are equivalent to that of DDLT requires further observations. The clinical course following LDLT may be affected by the genetic background shared between the recipient and the living related donor.
Tamura
Sumihito
S
Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Sugawara
Yasuhiko
Y
Kaneko
Junichi
J
Togashi
Junichi
J
Matsui
Yuichi
Y
Yamashiki
Noriyo
N
Kokudo
Norihiro
N
Makuuchi
Masatoshi
M
D015209:Cholangitis, Sclerosing / Q000601:surgery; D002779:Cholestasis / Q000601:surgery*; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000601:surgery; D016031:Liver Transplantation; D019520:Living Donors; D012008:Recurrence; D016896:Treatment Outcome
Am J Transplant. 2005 Feb;5(2):307-13
15643990
Hepatology. 1999 Jun;29(6):1643-8
10347102
Hepatol Res. 2007 Oct;37 Suppl 3:S449-54
17931201
Transplant Proc. 2004 Oct;36(8):2297-8
15561226
Transpl Int. 1999;12(5):383-6
10552006
J Hepatobiliary Pancreat Surg. 1999;6(3):245-53
10526059
Hepatol Res. 2007 Oct;37 Suppl 3:S463-9
17931204
Hepatology. 1998 Jul;28(1):33-8
9657093
N Engl J Med. 1996 Nov 21;335(21):1570-80
8900092
Liver Transpl. 2005 Jan;11(1):111-3
15690546
Nephrol Dial Transplant. 2001 Jan;16(1):166-8
11209015
J Hepatol. 1993 Jun;18(2):173-84
8409333
J Hepatol. 2003 Aug;39(2):142-8
12873808
Liver Transpl. 2003 Jul;9(7):737-40
12827562
Liver Transpl. 2007 Jan;13(1):80-90
16964594
Transplantation. 2001 Sep 27;72(6):1087-91
11579305
Surgery. 2002 Jan;131(1 Suppl):S195-9
11821810
J Hepatol. 1996 Aug;25(2):129-34
8878772
Transplantation. 1998 Nov 27;66(10):1313-6
9846514
Gastroenterology. 2005 Feb;128(2):297-303
15685541
J Am Coll Surg. 2003 Nov;197(5):765-9
14585411
N Engl J Med. 1995 Apr 6;332(14):924-33
7877651
Liver Transpl. 2006 Jul;12(7):1077-83
16598784
Transplant Proc. 2004 Jun;36(5):1492-3
15251367
Transplant Proc. 1998 Nov;30(7):3321-3
9838468
Liver Transpl. 2001 Jul;7(7):588-95
11460225
J Hepatobiliary Pancreat Surg. 2004;11(3):211-4
15235897
Transpl Int. 2005 Jul;18(7):794-9
15948857
Lancet. 1994 May 14;343(8907):1233-4
7909905
Hepatogastroenterology. 1999 Sep-Oct;46(29):2951-4
10576379
N Engl J Med. 2005 Sep 22;353(12):1261-73
16177252
Liver Transpl. 2001 Nov;7(11 Suppl 1):S99-108
11689782
Hepatology. 2006 Sep;44(3):746-64
16941705
Liver Transpl. 2007 Jun;13(6):938-9
17538993
Hepatology. 1994 Jul;20(1 Pt 1):126-34
8020881
Hepatology. 1999 Apr;29(4):1050-6
10094945
Scand J Gastroenterol. 1999 Jul;34(7):714-22
10466884
Am J Gastroenterol. 2004 Mar;99(3):538-42
15056099
N Engl J Med. 2007 Oct 11;357(15):1524-9
17928600
Transplant Proc. 2003 Nov;35(7):2431-4
14611979
Hepatology. 1999 Jul;30(1):325-32
10385674
Hepatology. 2001 Jan;33(1):22-7
11124816
Yonsei Med J. 2004 Dec 31;45(6):1162-8
15627313
Liver Transpl. 2000 Jul;6(4):489-94
10915173
Liver Int. 2007 Feb;27(1):86-94
17241386
J Hepatobiliary Pancreat Surg. 2000;7(4):380-94
11180859
World J Gastroenterol. 2005 Jan 7;11(1):7-16
15609388